AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02564354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-010
Description: Single-stranded RNA antisense oligonucleotide in isoosmolar solution
Study NCT01743625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COV155
Description: COV155 tablets
Study NCT01743625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00977054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFPP + Peg-IFN + RBV
Description: Double filtration plasmapheresis: day 1,2,4,8,9 from the onset of treatment (4 hours for each session) Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight \< 75 kg, 1,000 mg/day; body weight loss >= 75 kg, 1,200 mg/day)
Study NCT00977054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN + RBV
Description: Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight \< 75 kg, 1,000 mg/day; body weight loss >= 75 kg, 1,200 mg/day)
Study NCT01173198 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WAVEFRONT Optimized LASIK
Description: 30 patients
Study NCT01173198 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WAVEFRONT GUIDED LASIK
Description: 30 patients
Study NCT04283721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Ten-minutes educational video on epidural/spinal analgesia benefits and side effects (sample video link: https://youtu.be/jAhoKhvcbP4). The informational video will be administered by co-investigators, who are anaesthesiologists. The video will be shown on an institutional iPad that will be thoroughly disinfected by the co-investigators before and after each use. Co-investigators will receive training on the disinfection process, and each disinfection will be documented on a logbook, dated and signed by the co-investigators.
Study NCT03126045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard needle
Description: Patients will perform a spinal punction with a standard needle, used in the usual practice. The standard needles have the following characteristics : BD 22 G x 3 ½ in, 90mm, Quincke spinal needle, Black hub.~When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture.
Study NCT03126045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atraumatic needle
Description: Patients will perform a spinal punction with an atraumatic needle, used in the hematological service of the CHU of Saint-Etienne. The atraumatic needles have the following characteristics : Vygon 24 G × 3 ½ in, 90mm, Whitacre Pencil Point Spinal Needle, Purple hub.~When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture.
Study NCT02202668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRS
Description: TRS measurements of subcutaneous deep wound soft tissue and underlying bone will be collected at the same standard locations that are used to measure wound dimensions. The probe will never be in contact with the wound, but we will sterilize the probe head in advance in order to ease potential concerns regarding equipment sterility. A single point TRS measurement can be obtained in less than 60 seconds. At a minimum we will collect measurements at the geometric center of the wound as well as at the 6 and 12 and 3 and 9 ulcer coordinates. These coordinates are commonly used to estimate ulcer dimensions. It is anticipated that the PhAT probe will be used with a beam diameter of 7.5 mm. It is possible that the incident laser beam diameter will need to be adjusted (7.5 mm to 6.0 mm) to accommodate smaller wounds. If incident laser beam diameter adjustment is necessary we will also adjust the laser intensity to maintain the maximum permissible exposure of 0.3 W/cm2 per ANSI guidelines.
Study NCT03021954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet rich plasma is an autologous blood with high amount of platelet. It produced by obtaining patient's whole blood and processed by centrifugation and activation by CaCl2.
Study NCT00069238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Campath)
Description: Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles.
Study NCT00069238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH
Description: Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.
Study NCT02652013 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cognitive evaluation
Study NCT02652013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive evaluation
Study NCT01001832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) abatacept
Description: IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141.
Study NCT01001832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous (SC) abatacept
Description: Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks
Study NCT01987141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMR Intervention
Description: Electronic medical record flag/notification in the patient's chart
Study NCT01453426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 Dose 1
Study NCT01453426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 Dose 2
Study NCT00526487 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zenith® Dissection Endovascular System
Description: The Zenith® Thoracic Dissection Study is a clinical trial to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of dissections (length-wise tear) of the descending thoracic aorta. The Zenith® Dissection Endovascular System is comprised of the Zenith TX2® TAA Endovascular Graft and the Zenith® Dissection Endovascular Stent. Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the graft and the dissection stent into place in the aorta.
Study NCT00526487 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Endovascular Repair
Description: Endovascular Repair
Study NCT02430688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Study NCT02430688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study NCT00208923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan, Cyclophosphamide and Fludarabine
Description: * Bulsufan 1mg/kg/dose P.O. every 6 hours for 4 days. If intravenous, busulfan dose will be 0.8 mg/kg every 6 hours for 16 doses.~* Fludarabine 40 mg/m2 a day for 5 days via IV over 2 hours, dose based on weight.~* Cyclophosphamide given via IV over 1 hour at dose of 60 mg/kg/day for 2 consecutive days.
Study NCT02718937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTA-C585 oral capsule
Study NCT02718937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo capsules
Study NCT02700763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18F]dabrafenib molecular imaging
Description: A \[18F\]dabrafenib dynamic PET scan of the brain (60 minutes) and static total body PET scan will be performed at baseline.
Study NCT00343135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin/clavulanate potassium 1gm
Description: amoxicillin/clavulanate potassium 1gm
Study NCT00194519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic acyclovir
Description: 400 mg twice-daily oral
Study NCT00194519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice-daily oral
Study NCT02920931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Study NCT02920931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil
Study NCT01183078 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: free-hand
Description: Free-hand technique utilizes x-rays to find screw holes.
Study NCT01183078 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wand technique
Description: Wand technique is utilized to find screw holes.
Study NCT03791671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individual balance training
Description: One physiotherapist trains one Patient nearby a bar. The tasks changes in gage, visual feedback, vestibular feedback and underground. The Positions will be hodl for 10-30 seconds.
Study NCT03791671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group balance training
Description: Like the individual balance training
Study NCT00985153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Description: A Single 0.5 mL subcutaneous injection at Day 0
Study NCT00985153 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Varivax
Description: A Single 0.5 mL subcutaneous injection at Day 0
Study NCT00985153 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: M-M-R II
Description: A Single 0.5 mL subcutaneous injection at Day 0
Study NCT02748720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RFM (device) Visible
Description: Will measure the expire tidal volume, end tidal CO2 and peak pressure changes according to clinical improvement and tidal volume
Study NCT02640157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 coformulated with ABT-530
Study NCT02640157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Tablet
Study NCT02640157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Tablet
Study NCT01740141 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plexus brachialis block
Study NCT05208671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NOURISH Food Box
Description: Selection of healthy groceries designed to reduce chronic inflammation and improve insulin resistance with healthy cooking/self-care curriculum
Study NCT01401907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early palliative care
Description: patient assigned to the intervention will receive early palliative care along with standard oncology care.
Study NCT01323634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg
Description: inhalation powder
Study NCT01323634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate 250mcg/ salmeterol 50mcg
Description: inhalation powder
Study NCT02607696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Hemitartarate
Study NCT02409368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01723384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03223896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone hydrochloride 20mg/ml
Description: Nasal spray
Study NCT02737709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin regimen
Description: Chemotherapy regimen:Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S；Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection.
Study NCT00101881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Defibrillation (biphasic versus monophasic shock)
Description: Administration of monophasic or biphasic waveform defibrillation
Study NCT01116882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Study NCT01116882 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Study NCT02673840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen
Description: 2 mg of Ketotifen, twice a day for a total of ten (10) doses
Study NCT02673840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical tablets containing 0 mg of Ketotifen, twice a day for a total of ten (10) doses
Study NCT02879422 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: genetic analysis
Study NCT01879215 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramedullary nailing of the tibia
Description: Standard care surgery
Study NCT03069612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS administered bilaterally to the DLPFC at 20 Hz, 90% RMT, 25 trains
Study NCT03069612 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS administered bilaterally to the DLPFC at 20 Hz, 90% RMT, 25 trains
Study NCT01530165 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Life style intervention
Description: The main goals of intervention will focus mainly on: Weight reduction ≥ 5% , moderate intensity physical activity ≥ 30 min daily, dietary fat \<30 proportion of total energy, saturated fat \<10%, Fiber ≥ 15g/1,000 kcal There will be 9 sessions during the two years course of follow-up
Study NCT01001026 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Arepanrix
Description: Adults: One dose Arepanrix vaccine given IM (0.5 mL)
Study NCT01001026 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Arepanrix
Description: Children: Two doses of Arepanrix vaccine given IM (0.25 mL) three weeks apart
Study NCT03056222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation catheter
Description: Ablation of paroxysmal atrial fibrillation
Study NCT02323217 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]BU99008
Description: Baseline Scan, Test-ReTest or Dosimetry
Study NCT02323217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idazoxan
Description: Idazoxan block of \[11C\]BU99008
Study NCT02323217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isocarboxazid
Description: Isocarboxazid block of \[11C\]BU99008
Study NCT03549182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATD treatment
Description: oral administration of ATD (100g)(Acute Tryptophan Depletion)
Study NCT03549182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo treatment
Description: oral administration of placebo (102.3g)
Study NCT02480387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir FDC
Study NCT04027517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTZ-951
Description: Oral tablet~* Dose adjustments as maintenance dose is allowed according to the result of Hb level.
Study NCT04027517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin Alfa
Description: Intravenous administration~* Dose adjustments as maintenance dose is allowed according to the result of Hb level.
Study NCT02839200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 5 mg
Description: Capsule for oral administration containing ACT-541468 at a strength of 5 mg
Study NCT02839200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 10 mg
Description: Capsule for oral administration containing ACT-541468 at a strength of 10 mg
Study NCT02839200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 25 mg
Description: Capsule for oral administration containing ACT-541468 at a strength of 25 mg
Study NCT02622958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH94B
Description: PH94B is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg PH94B).~Dosing is sex-specific:~* Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~* Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg
Study NCT02622958 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg Placebo).~Dosing is sex-specific:~* Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~* Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg
Study NCT01941797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interruption of oral hygiene
Study NCT01941797 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interruption of oral hygiene
Study NCT04842656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post isometric relaxation
Description: Patients in group B will receive post isometric relaxation technique. Patient lying in supine position, with the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra lateral knee (the leg on the side to be treated is crossed over the other). Therapist places one hand on the contra lateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis (PIR MET). The starting position will be the 1st sign of resistance towards end range. Therapist Force will be same as patient's force. Initial effort is approximately 20% of patient's strength. Duration of contraction is 7-10 seconds with three repetitions
Study NCT04842656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active release technique alongwith conventional treatment
Description: Patients in Group A will receive active release technique.ART will be applied with patient in prone lying, knee flexed at 90. The therapist will place his elbow tip on taut band of piriformisand direct pressure isapplied, patient is then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This will be repeated 5-7 times.
Study NCT04278001 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dual 24-hour ABPM
Description: Dual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207).
Study NCT03695666 — intervention group
Intervention type: OTHER
Intervention: Clerical policy
Description: Clerical policy introduction
Study NCT02737839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepping On Education Program
Study NCT02737839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visit
Study NCT02737839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Questionnaire
Description: -Includes questions about demographics, activity level, performance status, falls, medication, comorbidities, hearing, vision, pain, and neuropathy
Study NCT02737839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mini-Balance Evaluation Systems Test
Description: * The Mini-BESTest includes 14-items that assess balance across four domains: 1) anticipatory postural adjustments, 2) reactive postural responses, 3) sensory orientation, and 4) stability in gait. Each item is rated on a 0-2 scale with 0 indicating poor balance and 2 indicating no impairment. The total possible score on the Mini-BESTest is 28 points~* Balance testing will take approximately 15 minutes.
Study NCT02737839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GAITRite
Description: * Gait will be assessed using the 4.87-m GAITRite~* The GAITRite is a computerized mat that allows for measurement of spatiotemporal measures (e.g., gait velocity, stride length) of gait. We will measure gait in the following conditions: 1) comfortable forward, 2) fast-as-possible, and 3) dual-task. For comfortable forward, participants will be asked to walk at their self-perceived normal pace. For fast-as-possible, participants will be asked to walk as quickly and safely as possible. For dual-task, participants will be asked to walk at their comfortable pace forward while saying as many words that begin with a letter given to them just prior to the start of the trial. Participants will complete five trials of each condition. Gait testing will take approximately 15 minutes.
Study NCT02737839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Precise measure of movement testing
Description: We will conduct additional movement-based testing with participants wearing small, portable sensors (APDM, Inc., Portland, OR). These sensors allow for precise measurement of movement characteristics. The sensors will be worn on the outside of clothing and will be placed on the following body locations: 1) sternum, 2) low back, 3) right wrist, 4) left wrist, 5) right ankle, and 6) left ankle. The participants will wear these sensors during the following movement tasks: 1) Two Minute Walk Test, 2) Timed Up \& Go, 3) Dual Timed Up \& Go, 4) Stand and Walk (SAW), and 5) 360 Degree Turn test. These sensors will allow for capture of precise measures postural sway, arm swing, gait variability, and many other variables the proposed movement tasks.